TY - JOUR
T1 - Teratogenic effects of antiepileptic drugs
AU - Tomson, Torbjörn
AU - Battino, Dina
PY - 2012/9
Y1 - 2012/9
N2 - Most women with active epilepsy need treatment with antiepileptic drugs during pregnancy. Antiepileptic drugs are also frequently used for other indications, such as migraine, pain syndromes, and psychiatric disorders, which are prevalent among women of childbearing age. Possible teratogenic effects of antiepileptic drugs are therefore of wide concern and the risks imposed by the drugs must be weighed against the risks associated with the disorder being treated. Adverse drug effects on the fetus can present as fetal loss, intrauterine growth retardation, congenital malformations, impaired postnatal development, and behavioural problems. For optimum use of antiepileptic drugs in women of childbearing age and rational management of epilepsy during pregnancy, a thorough understanding of the teratogenic effects of antiepileptic drugs and knowledge of the differences in risks between various treatment options are needed.
AB - Most women with active epilepsy need treatment with antiepileptic drugs during pregnancy. Antiepileptic drugs are also frequently used for other indications, such as migraine, pain syndromes, and psychiatric disorders, which are prevalent among women of childbearing age. Possible teratogenic effects of antiepileptic drugs are therefore of wide concern and the risks imposed by the drugs must be weighed against the risks associated with the disorder being treated. Adverse drug effects on the fetus can present as fetal loss, intrauterine growth retardation, congenital malformations, impaired postnatal development, and behavioural problems. For optimum use of antiepileptic drugs in women of childbearing age and rational management of epilepsy during pregnancy, a thorough understanding of the teratogenic effects of antiepileptic drugs and knowledge of the differences in risks between various treatment options are needed.
UR - http://www.scopus.com/inward/record.url?scp=84865135028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865135028&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(12)70103-5
DO - 10.1016/S1474-4422(12)70103-5
M3 - Article
C2 - 22805351
AN - SCOPUS:84865135028
VL - 11
SP - 803
EP - 813
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 9
ER -